AJOKE KAZEEM: Open Payments
NPI 1588241558 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,697 in 37 payments from 12 companies in 2025. Trend: 2023 $1,893 · 2024 $1,886 · 2025 $2,697
Food & beverage: $2,697
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 4 | $426 |
| E.R. Squibb & Sons, L.L.C. | 6 | $379 |
| Otsuka America Pharmaceutical, Inc. | 4 | $288 |
| Neurocrine BioSciences, Inc. | 4 | $281 |
| Supernus Pharmaceuticals, Inc. | 4 | $273 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $272 |
| Alkermes, Inc. | 2 | $211 |
| Axsome Therapeutics, Inc. | 2 | $205 |
| Vanda Pharmaceuticals Inc. | 4 | $159 |
| Janssen Pharmaceuticals, Inc | 2 | $149 |
Products named: COBENFY, AUSTEDO XR, INGREZZA, Qelbree, CAPLYTA, LYBALVI, Auvelity, REXULTI.
Industry payments across TX — which companies pay providers there.
